Aktuellt
SENASTE
Redeye endorses today’s news that Egetis has filed a marketing authorization application (“MAA”) for Emcitate, targeting MCT8 deficiency, to EMA for approval in the EU. This is precisely in line with previous communication (9th of October). We expect an approval in H2 2024. We have argued that advancements with the EU application is a key catalyst in the near term that could enhance shareholder sentiment and we thus expect a positive share price reaction following the reported progress in line with expectations.
LÄS MER
